SLC5A2 and type 1 diabetes mellitus: Our current analysis evaluated the changes in individual and grouped plasma amino acid levels and related metabolites in a cohort of patients with T1D in response to (1) hyperglycemia, (2) SGLT2 inhibitor empagliflozin under clamped euglycemia, and (3) empagliflozin under clamped hyperglycemia.